Alvotech Inks Commercialization Agreement With Advanz Pharma For Proposed Biosimilar To Eylea LD/HD In Europe
Portfolio Pulse from Benzinga Newsdesk
Alvotech has signed a commercialization agreement with Advanz Pharma for its proposed biosimilar to Eylea in Europe. Advanz Pharma will handle market registration, commercialization, and patient access in Europe.
June 18, 2024 | 8:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alvotech has entered into a partnership with Advanz Pharma to commercialize its biosimilar to Eylea in Europe. This agreement could enhance Alvotech's market presence and revenue potential in the European market.
The partnership with Advanz Pharma is likely to boost Alvotech's market presence in Europe, potentially increasing its revenue. Advanz Pharma's expertise in market registration and patient access will be crucial for the successful commercialization of the biosimilar.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100